Saskia Litière, Biostatistician at the EORTC, discusses the ongoing evaluation of RECIST with Helen Saul
10 Feb 2015
Hear Saskia Litière, EORTC Biostatistician, discuss “The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumors 1.1 database”, an article published in European Journal of Cancer (2015) 51, 1847-1853.
Related News
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer
17 May 2026
Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma
1 May 2026
EORTC’s presence at ESTRO 2026
30 Apr 2026
Independent, academic cancer trials are vital to improve patient outcomes worldwide
28 Apr 2026
EORTC Imaging Group Becomes the Diagnostic and Therapeutic Imaging Group
24 Apr 2026
